References
- Codolosa J, Acharjee S, Figueredo V. Update on ranolazine in the management of angina. Vasc Health Risk Manag. 2014;10:353.
- Jerling M. Clinical Pharmacokinetics of Ranolazine. Clin Pharmacokinet. 2006;45:469–91.
- Bengel P, Ahmad S, Sossalla S. Inhibition of late sodium current as an innovative antiarrhythmic strategy. Curr Heart Fail Rep. 2017;14:179–186.
- Zhao G, Walsh E, Shryock JC, et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011;57:639–647.
- Maier LS, Layug B, Karwatowska-Prokopczuk E, et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction. JACC Heart Fail. 2013;2:115–122.